Connection
Michael McDermott to Hypoglycemic Agents
This is a "connection" page, showing publications Michael McDermott has written about Hypoglycemic Agents.
|
|
Connection Strength |
|
 |
|
 |
|
0.567 |
|
|
|
-
Trujillo JM, Wettergreen SA, Nuffer WA, Ellis SL, McDermott MT. Cardiovascular Outcomes of New Medications for Type 2 Diabetes. Diabetes Technol Ther. 2016 12; 18(12):749-758.
Score: 0.325
-
Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 01; 51(8):501-14.
Score: 0.242